Transplant News and Research

RSS

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.

29 Apr 2010

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.

29 Apr 2010

Study examines world-wide use of HSCT

An examination of the world-wide use of hematopoietic stem cell transplantation, which involves transplantation of blood stem cells derived from the bone marrow or blood, finds that there are significant differences in transplant rates between countries and continental regions by indication and donor type, and that HSCT is most frequently used in countries with higher gross national incomes and governmental health care expenditures, according to a study in the April 28 issue of JAMA.

28 Apr 2010

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2010. The company also highlighted recent product development activities and planned milestones.

28 Apr 2010

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

The Juvenile Diabetes Research Foundation announced today that it is partnering with Living Cell Technologies, a New Zealand-based biotechnology company focused on developing cell based therapeutics, in a Phase II clinical trial to study the safety and effectiveness of transplanting encapsulated insulin-producing cells from pigs as a treatment for type 1 diabetes with significant hypoglycemia unawareness.

28 Apr 2010

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has published results from its Phase II GEMINI study in the Proceedings of the National Academy of Sciences (PNAS). These data, previously presented at the International Symposium on Respiratory Viral Infections in Singapore in 2008, showed human proof of concept with an RNAi therapeutic in a randomized, double blind, placebo-controlled study.

27 Apr 2010

Jefferson Medical College surgeon uses artificial liver assist device as bridge to transplantation

Cataldo Doria, M.D., Ph.D., Nicoletti Family Professor of Transplant Surgery at Jefferson Medical College of Thomas Jefferson University, and director of the Division of Transplantation at Thomas Jefferson University Hospital is the first transplant surgeon in the United States to use a new totally artificial liver assist device as a bridge to transplantation.

27 Apr 2010

ThermoGenesis extends reach of stem cell regenerative medicine market into Asia, Central and South America

ThermoGenesis Corp., a leading supplier of innovative products for processing and storing adult stem cells, announced today that it has signed two new distribution agreements that will further extend its global reach into Asia and Central and South America for its offerings in the bone marrow stem cell regenerative medicine market. The Company has now completed four new distribution agreements in the past 90 days, significantly enhancing its ability to market and sell its products throughout the world.

27 Apr 2010

Cedars-Sinai Heart Institute presents new findings on heart transplantation rejection factors

Physician scientists at the Cedars-Sinai Heart Institute are presenting new findings on heart transplantation rejection factors such as race and gender, the effects of pre-transplant smoking and whether homeless organ donors put recipients at higher risk for complications. The presentations will take place April 21 - 24 in Chicago during the 30th Annual Scientific Meeting of the International Society of Heart and Lung Transplantation.

26 Apr 2010

Successful full face transplant in a 22 hour long operation: Barcelona

In a recent development a team of 30 Spanish surgeons have succeeded in a World’s first full face transplant. The patient had accidentally injured a large part of his face with a shotgun five years ago. This had left him disfigured an unable to breathe, swallow or talk properly. He has undergone nine unsuccessful operations before this operation was planned. In this operation he received the whole of his facial skin, muscles, nose, lips, teeth and cheek bones from a donor in a 22 hour operation at the Vall d'Hebron University Hospital on 20th March. He is on his way to recovery now. This is not the first face transplant but the first full face transplant and also the most complex of its kind.

26 Apr 2010

Niagara Falls lights up for National Organ and Tissue Donor Awareness Week

On April 21, 1994, two-year-old Stuart Herriott succumbed to head injuries after an accident and his parents consented to organ donation. His heart, liver and both kidneys were transplanted. Sixteen years later, the Herriott family, including Stuart's aunt, Linda Rumble, will be among the many supporters of organ and tissue donation gathering on both sides of the Canada -US boarder today to help raise awareness of the continuing need for organ and tissue donors.

24 Apr 2010

HeartWare International presents clinical trial data of Ventricular Assist System at ISHLT annual meeting

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced that data from its international clinical trial and commercial experience of the HeartWare® Ventricular Assist System showed a survival rate of 90 percent at six months and an actuarial survival rate of 86 percent at 12 months post implant.

24 Apr 2010

AlloMap molecular expression test reduces need for invasive heart-muscle biopsies

Monitoring rejection in heart transplantation patients with a simple blood test co-developed by NewYork-Presbyterian Hospital/Columbia University Medical Center physician-scientist Dr. Mario Deng in 2005 can safely reduce their need for invasive heart-muscle biopsies, a new study has found.

24 Apr 2010

Continuous flow mechanical circulatory support devices improve outcomes in patients awaiting heart transplants

New data show improved outcomes, better survival rates and lower costs with the use of continuous flow mechanical circulatory support devices in patients awaiting heart transplants. Research will be presented this week during symposia at the International Society for Heart and Lung Transplantation (ISHLT) 30th Annual Meeting and Scientific Session at the Hilton Chicago.

24 Apr 2010

Baptist Hospital East adopts CardiacAssist's TandemHeart System

CardiacAssist Inc. announced today that Baptist Hospital East has adopted the company's TandemHeart System.

23 Apr 2010

Facet Solutions announces data from ACADIA lumbar stenosis pilot study

Facet Solutions, Inc. today announced that it has finished compiling two year data from its lumbar stenosis pilot study in the US. At two years, patients in the ACADIA™ study experienced significant and sustained improvement in Oswestry Disability Index, VAS back pain and VAS leg pain. There were no re-operations in any of the patients, and all patients met the definition of success for ODI improvement.

23 Apr 2010

Team liberates cellular hostages by silencing Toxoplasma gondii's back-seat driving

Scientists studying a cunning parasite that has commandeered the cells of almost half the world's human population have begun to zero in on the molecular signals that must be severed to free the organism's cellular hostages.

23 Apr 2010

QF-CMV test helps predict transplant recipients at increased risk of CMV disease after surgery

New international guidelines published in the journal Transplantation reinforce the use of a new type of blood test to assess cytomegalovirus (CMV) risk in solid organ transplant recipients (i.e. transplant recipients). This blood test, QuantiFERON®-CMV (QF-CMV), is the first commercially-available blood test to allow physicians to monitor a person's risk of CMV disease. Most commonly used in the transplant setting, QF-CMV may predict which transplant recipients are at increased risk of CMV disease after transplant surgery.

23 Apr 2010

New blood test to determine patients at low risk for rejection of transplanted hearts

After his heart transplant in 2005, Ramon Llenado underwent a biopsy every week, then every month, then every three months. Most heart transplant patients face a lifetime of these invasive tests, which involve snipping out tiny pieces of heart to check for possible organ rejection.

23 Apr 2010

Astellas Pharma extends tender offer for OSI Pharmaceuticals

Astellas Pharma Inc. announced today that it has extended its all-cash tender offer for $52 per share for all of the currently outstanding shares of common stock (including the associated stock purchase rights) of OSI Pharmaceuticals, Inc. to 5:00 p.m. New York City time on Monday, May 17, 2010, unless further extended.

23 Apr 2010

Transplant News and Research

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Study examines world-wide use of HSCT

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Jefferson Medical College surgeon uses artificial liver assist device as bridge to transplantation

ThermoGenesis extends reach of stem cell regenerative medicine market into Asia, Central and South America

Cedars-Sinai Heart Institute presents new findings on heart transplantation rejection factors

Successful full face transplant in a 22 hour long operation: Barcelona

Niagara Falls lights up for National Organ and Tissue Donor Awareness Week

HeartWare International presents clinical trial data of Ventricular Assist System at ISHLT annual meeting

AlloMap molecular expression test reduces need for invasive heart-muscle biopsies

Continuous flow mechanical circulatory support devices improve outcomes in patients awaiting heart transplants

Baptist Hospital East adopts CardiacAssist's TandemHeart System

Facet Solutions announces data from ACADIA lumbar stenosis pilot study

Team liberates cellular hostages by silencing Toxoplasma gondii's back-seat driving

QF-CMV test helps predict transplant recipients at increased risk of CMV disease after surgery

New blood test to determine patients at low risk for rejection of transplanted hearts

Astellas Pharma extends tender offer for OSI Pharmaceuticals

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News